CFH and atypical hemolytic-uremic syndrome: This mechanism mirrors the pathogenesis of aHUS, where dysregulation of the alternative complement pathway, often due to genetic mutations or acquired defects in regulatory proteins like factor H, factor I, or membrane cofactor protein (MCP/CD46), leads to uncontrolled complement activation.